U.S IPO Karuna Therapeutics gives huge returns to investors

Karuna Therapeutics is a state-of-the-art clinical-stage biopharmaceutical company mainly focused on developing original therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need.

As the company performed well in November month, the early share holders of Karun observed an increase of 420% returns to the stock priced at $16 a share in the month of June. The early investors will soon ge....